FATE

Fate Therapeutics Inc

2.06

Oct 20 • 3:59 PM ET +0.20 (10.75%)

2.05

Aftermarket • 7:30 PM ET -0.01 (-0.49%)

Healthcare Biotechnology USA Micro NASD

Peers: IPSC ALLO NKTX SANA ARTV CABA KYTX CRBU CLLS ACET

| Held by: VTI VXF SCHA VHT IWC PRFZ BUSM AVSC SCHB DFMC

Scroll to Statements

Index	-
Market Cap	246.83M
Enterprise Value	168.73M
Income	-126.00M
Sales	6.49M
Book/sh	1.31
Cash/sh	1.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	161
IPO	Oct 01, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	38.03
P/B	1.57
P/C	1.61
P/FCF	-
EV/EBITDA	-
EV/Sales	26.00
Quick Ratio	4.85
Current Ratio	4.85
Debt/Eq	0.49
LT Debt/Eq	0.46
Option/Short	Yes / Yes

EPS (ttm)	-1.05
EPS next Y	-1.05
EPS next Q	-0.27
EPS this Y	7.39%
EPS next Y	1.28%
EPS next 5Y	1.61%
EPS past 3/5Y	26.67% 11.42%
Sales past 3/5Y	-58.98% -26.71%
EPS Y/Y TTM	27.52%
Sales Y/Y TTM	-23.36%
EPS Q/Q	12.84%
Sales Q/Q	9.18%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	6.47% 55.35%

Insider Own	4.67%
Insider Trans	-2.39%
Inst Own	58.05%
Inst Trans	-2.02%
ROA	-39.89%
ROE	-60.75%
ROIC	-56.20%
Gross Margin	-84.69%
Oper. Margin	-2058.08%
Profit Margin	-1941.09%
SMA20	-5.82%
SMA50	-13.06%
SMA200	7.57%
Trades

Shs Outstand	116.69M
Shs Float	114.23M
Short Float	9.42%
Short Ratio	6.72
Short Interest	10.76M
52W High	3.23 -36.22%
52W Low	0.95 116.84%
Volatility	9.17% 7.25%
ATR (14)	0.16
RSI (14)	43.21
Beta	2.65
Rel Volume	1.11
Avg Volume	1.60M
Volume	1,771,860

Perf Week	3.00%
Perf Month	-18.58%
Perf Quarter	-20.16%
Perf Half Y	52.59%
Perf YTD	109.65%
Perf Year	33.77%
Perf 3Y	3.00%
Perf 5Y	-96.54%
Perf 10Y	-17.60%
Recom	2.00
Target Price	6.07
Prev Close	1.86
Price	2.06
Change %	10.75%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-26	Resumed	Jefferies	Buy
Oct-31-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-27-25	Upgrade	Wedbush	Neutral → Outperform	$7
Nov-18-24	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90

Show Previous Ratings

Oct-12-26 07:00AM	Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies (GlobeNewswire)
Oct-07-26 09:48AM	Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire) -6.11%
Oct-02-26 07:00AM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-26 07:00AM	Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences (GlobeNewswire)
Sep-25-26 07:00AM	Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN (GlobeNewswire)
07:00AM	Loading…
Sep-16-26 07:00AM	Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 (GlobeNewswire)
Sep-09-26 07:00AM	Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting (GlobeNewswire)
Sep-03-26 07:00AM	Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference (GlobeNewswire)
Sep-02-26 08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
Aug-14-26 07:00AM	Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis (GlobeNewswire)
Aug-13-26 08:41AM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press) -7.35%
08:30AM	Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
Aug-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-26 04:52PM	FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials (Stocktwits) +6.14%
08:30AM	Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate (GlobeNewswire)
08:30AM	Loading…
Jul-06-26 08:30AM	Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting (GlobeNewswire)
Jul-01-26 04:05PM	Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences (GlobeNewswire) +11.85%
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire) +11.57%
Jun-15-26 08:30AM	Fate Therapeutics Appoints Laura Hamill to Board of Directors (GlobeNewswire)
Jun-04-26 08:30AM	Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting (GlobeNewswire)
Jun-02-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.20% -13.62%
Jun-01-26 08:30AM	Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting (GlobeNewswire)
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire) +7.98%
May-21-26 08:30AM	Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases (GlobeNewswire) +14.13%
May-20-26 09:50AM	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets (PR Newswire)
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) +9.25%
May-13-26 08:35AM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press) -5.11%
08:30AM	Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
May-11-26 08:30AM	Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting (GlobeNewswire) -8.79%
May-05-26 08:30AM	Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 (GlobeNewswire) +31.11%
09:00AM	Loading…
May-04-26 09:00AM	Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases (GlobeNewswire) +17.65%
May-01-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +22.40%
Apr-30-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR - East 2026 Meeting (GlobeNewswire)
Apr-16-26 09:00AM	Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting (GlobeNewswire) +6.20%
Apr-09-26 09:00AM	Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences (GlobeNewswire) +7.63%
Apr-02-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
Mar-04-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.84%
Mar-03-26 04:05PM	Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire) -8.67%
10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-26-26 01:30PM	Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.41%
09:15AM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
09:00AM	Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-03-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.69%
Jan-26-26 10:16AM	Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets (PR Newswire)
Jan-05-26 04:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-08-25 08:00AM	Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs (GlobeNewswire)
Nov-25-25 08:00AM	Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 09:40AM	Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
08:30AM	Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Nov-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56% -8.40%
10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-26-25 11:30AM	Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy (GlobeNewswire)
Oct-14-25 08:00AM	Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer (GlobeNewswire) +7.91%
Oct-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 08:00AM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -5.22%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire) -5.31%
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +20.69%
04:30PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-11-25 06:55PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-07-25 06:25PM	Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates (Zacks) -5.76% -5.99%
Aug-06-25 07:45AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 04:57PM	Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data (Insider Monkey)
07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-03-25 01:05PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 11:30AM	Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? (Zacks) -9.68%
Jun-11-25 09:00AM	Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress (GlobeNewswire) -7.19%
Jun-10-25 10:23AM	Top Cancer Stocks to Supercharge Your 2025 Portfolio (Zacks) +9.87%
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire) -8.33% +7.44%
May-28-25 11:46PM	Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases (Insider Monkey)
05:54PM	Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress (GlobeNewswire)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
May-13-25 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.54%
04:01PM	Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
May-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65% -10.69%
Apr-29-25 09:25AM	Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting (GlobeNewswire) -6.40%
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks) +21.17%
Apr-14-25 08:00AM	Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) (GlobeNewswire) -12.80%
Apr-04-25 11:30AM	Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? (Zacks) +10.72%
Apr-02-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.69%
Mar-05-25 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +14.90%
04:12PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Mar-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.77%
Feb-17-25 10:00AM	Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-25 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +11.81% +7.75%
Feb-04-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.40%
Jan-03-25 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-12-24 11:30AM	Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? (Zacks) -11.70%
Dec-09-24 04:01PM	Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus (GlobeNewswire) -16.18%
Dec-03-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.15%
Dec-02-24 09:55AM	Fate Therapeutics makes Bob Valamehr president and CEO (Pharmaceutical Technology) -6.62%
Nov-29-24 01:05PM	Fate Therapeutics Announces Leadership Transition (GlobeNewswire)
Nov-26-24 04:01PM	Fate Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire) +10.74% +18.28%
Nov-18-24 08:05AM	Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence (GlobeNewswire) +12.38%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TAHL CINDY	See Remarks	Aug 04 '26	Sale	2.46	38,800	95,405	589,355	Aug 05 04:03 PM
Valamehr Bahram	President and CEO	Aug 04 '26	Sale	2.46	43,947	108,101	591,815	Aug 05 04:01 PM
TAHL CINDY	Officer	Aug 04 '26	Proposed Sale	2.46	38,800	95,405		Aug 04 04:40 PM
Valamehr Bahram	Officer	Aug 04 '26	Proposed Sale	2.46	43,947	108,101		Aug 04 04:34 PM
TAHL CINDY	See Remarks	May 20 '26	Sale	1.88	25,590	48,084	628,155	May 21 04:02 PM
Valamehr Bahram	President and CEO	May 20 '26	Sale	1.88	28,946	54,482	635,762	May 21 04:01 PM
Valamehr Bahram	Officer	May 20 '26	Proposed Sale	1.88	28,946	54,482		May 20 03:41 PM
TAHL CINDY	Officer	May 20 '26	Proposed Sale	1.88	25,590	48,084		May 20 03:38 PM
TAHL CINDY	See Remarks	May 06 '26	Option Exercise	1.25	166,664	207,997	653,745	May 07 04:00 PM
EPSTEIN ROBERT S	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:01 PM
RASTETTER WILLIAM H	Director	May 05 '26	Option Exercise	1.69	25,000	42,250	36,331	May 06 04:00 PM
TAHL CINDY	See Remarks	Jan 09 '26	Sale	1.06	10,589	11,275	387,081	Jan 12 04:04 PM
Valamehr Bahram	President and CEO	Jan 09 '26	Sale	1.07	5,190	5,557	329,708	Jan 12 04:03 PM
TAHL CINDY	Officer	Jan 09 '26	Proposed Sale	1.06	10,589	11,275		Jan 09 03:08 PM
Valamehr Bahram	Officer	Jan 09 '26	Proposed Sale	1.07	5,190	5,557		Jan 09 03:08 PM
MENDLEIN JOHN	Former Director	Dec 24 '25	Proposed Sale	1.01	38,428	38,881		Dec 29 02:44 PM

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Ph.D.Dr. Bahram Valamehr M.B.A.

MBAMr. Kamal Adawi M.S.

Chief Legal & Compliance Officer and Corporate SecretaryMs. Cindy R. Tahl J.D.

Senior Vice President of Human Resources & OperationsMs. Jessica Francis

Head of ResearchDr. Martin Hosking

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FATE

Fate Therapeutics Inc

Upgrade your Finviz experience